Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in Persistent or Chronic Primary ITP
NCT04200456Phase 3Terminated
- Sponsor
- UCB
- Start
- Jan 2020
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in primary immune thrombocytopenia (ITP) comparing Rozanolixizumab with Placebo (2 arms). Primary endpoint: Percentage of Participants With Durable Clinically Meaningful Platelet Response of ≥50x10^9/L, for at Least 8 Out of 12 Weeks During the Last 12 Weeks. Started Jan 2020; status: terminated.
02
Drugs
rozanolixizumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04200456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200456.